Welcome to the Neurology & Psychiatry Hub, a dedicated educational resource exploring the clinical management of amyloid-related imaging abnormalities (ARIA) in people receiving anti-amyloid therapies for Alzheimer's disease.
Managing ARIA requires timely clinical assessment and informed decisions about treatment interruption, ongoing MRI surveillance and the safe re-initiation of therapy. Understanding how to apply treatment guidelines, assess clinical symptoms alongside imaging findings and determine appropriate next steps is essential to maintaining patient safety while supporting treatment continuity.
Explore the educational resources below, including an expert-led video and an interactive multimedia snapshot, to strengthen your understanding of guideline-based ARIA management and support confident, evidence-informed treatment decisions throughout the Alzheimer's disease care pathway.
This activity has been supported by an independent education grant from Lilly. This education program is only available to healthcare professionals globally, excluding the United Kingdom.
